curanex pharmaceuticals inc - CYN

CYN

Close Chg Chg %
2.84 -0.38 -13.38%

Closed Market

2.46

-0.38 (13.38%)

Volume: 623.67K

Last Updated:

Dec 30, 2025, 4:00 PM EDT

Company Overview: curanex pharmaceuticals inc - CYN

CYN Key Data

Open

$2.80

Day Range

2.40 - 2.82

52 Week Range

2.40 - 151.50

Market Cap

$22.65M

Shares Outstanding

7.97M

Public Float

7.55M

Beta

0.06

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$595.08

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

504.85K

 

CYN Performance

1 Week
 
-15.17%
 
1 Month
 
-31.48%
 
3 Months
 
-61.32%
 
1 Year
 
-98.07%
 
5 Years
 
N/A
 

CYN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About curanex pharmaceuticals inc - CYN

Cyngn, Inc. engages in the development of autonomous driving software that can be deployed on multiple vehicle types in various environments. The company was founded by Kirt McMaster and Steve Kondik in 2013 and is headquartered in Mountain View, CA.

CYN At a Glance

Cyngn, Inc.
1344 Terra Bella Avenue
Mountain View, California 94043
Phone 1-650-924-5905 Revenue 368.14K
Industry Packaged Software Net Income -33,335,579.00
Sector Technology Services Employees 58
Fiscal Year-end 12 / 2025
View SEC Filings

CYN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 4.574
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 0.987
Enterprise Value to Sales -58.713
Total Debt to Enterprise Value -0.015

CYN Efficiency

Revenue/Employee 6,347.207
Income Per Employee -574,751.362
Receivables Turnover 0.481
Total Asset Turnover 0.017

CYN Liquidity

Current Ratio 7.438
Quick Ratio 7.395
Cash Ratio 6.867

CYN Profitability

Gross Margin -299.12
Operating Margin -6,200.957
Pretax Margin -9,055.186
Net Margin -9,055.186
Return on Assets -154.587
Return on Equity -695.413
Return on Total Capital 4,575.782
Return on Invested Capital -673.132

CYN Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital -43.841
Total Debt to Total Assets 1.061
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Curanex Pharmaceuticals Inc - CYN

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- 262.00K 1.49M 368.14K
Sales Growth
- - +468.44% -75.28%
-
Cost of Goods Sold (COGS) incl D&A
85.86K 791.69K 2.15M 1.47M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
85.86K 604.87K 931.28K 933.61K
Depreciation
82.39K 590.21K 903.91K 908.87K
Amortization of Intangibles
3.47K 14.66K 27.37K 24.74K
COGS Growth
-46.02% +822.13% +172.02% -31.77%
Gross Income
(85.86K) (529.69K) (664.28K) (1.10M)
Gross Income Growth
+46.02% -516.96% -25.41% -65.77%
Gross Profit Margin
- -202.17% -44.60% -299.12%
2021 2022 2023 2024 5-year trend
SG&A Expense
9.31M 18.87M 22.68M 21.73M
Research & Development
4.99M 9.48M 12.72M 11.26M
Other SG&A
4.32M 9.39M 9.96M 10.47M
SGA Growth
+13.39% +102.60% +20.19% -4.21%
Other Operating Expense
- - - -
-
Unusual Expense
- - (1.60M) 5.48M
-
EBIT after Unusual Expense
(7.80M) (19.40M) (23.35M) (28.31M)
Non Operating Income/Expense
7.17K 164.22K 534.71K (3.91M)
Non-Operating Interest Income
- - 44.10K 137.89K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 9.58K 1.12M
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - 9.58K 1.12M
-
Interest Capitalized
- - - -
-
Pretax Income
(7.80M) (19.24M) (22.81M) (33.34M)
Pretax Income Growth
+6.47% -146.64% -18.58% -46.14%
Pretax Margin
- -7,342.18% -1,531.66% -9,055.19%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(7.80M) (19.24M) (22.81M) (33.34M)
Minority Interest Expense
- - - -
-
Net Income
(7.80M) (19.24M) (22.81M) (33.34M)
Net Income Growth
+6.47% -146.64% -18.58% -46.14%
Net Margin Growth
- -7,342.18% -1,531.66% -9,055.19%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(7.80M) (19.24M) (22.81M) (33.34M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(7.80M) (19.24M) (22.81M) (33.34M)
EPS (Basic)
-4015.364 -8398.6372 -8556.75 -2521.5375
EPS (Basic) Growth
+6.65% -109.16% -1.88% +70.53%
Basic Shares Outstanding
1.94K 2.29K 2.67K 13.22K
EPS (Diluted)
-4015.364 -8398.6372 -8556.75 -2521.5375
EPS (Diluted) Growth
+6.65% -109.16% -1.88% +70.53%
Diluted Shares Outstanding
1.94K 2.29K 2.67K 13.22K
EBITDA
(9.31M) (18.80M) (22.41M) (21.89M)
EBITDA Growth
-13.39% -101.80% -19.25% +2.32%
EBITDA Margin
- -7,173.99% -1,505.03% -5,947.35%

Snapshot

Average Recommendation BUY Average Target Price 12.00
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate N/A
Last Quarter’s Earnings -1.20 Median PE on CY Estimate N/A
Year Ago Earnings -2,212.56 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A N/A N/A
Mean Estimate N/A N/A N/A N/A
High Estimates N/A N/A N/A N/A
Low Estimate N/A N/A N/A N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Curanex Pharmaceuticals Inc in the News